

2019-nCoV Spike protein RBD (N439K)

Catalog No: C19SD-G233H

N439K variant of SARS-CoV-2 spike protein has been reported in 34 countries since January 2021. N439K Spike protein has enhanced binding affinity to the hACE2 receptor through formation of new salt bridges, however there is no evidence for change in disease severity compared to wild type. Hence, as the new variants displace the first-wave virus, it is pivotal to evaluate their transmissibility, virulence and their possible tendency to escape antibody neutralization. SignalChem's Recombinant 2019-nCoV Spike protein S1 subunit, RBD (N439K) (319-541) was expressed in CHO cells using a C-terminal his tag.

Unique Selling Points




Biologically active




QA/QC tested for superior quality



Effective COVID19 research tool



Activity determined using functional ELISA



Competitors



Target Customers



Biopharma developing N439K targeting therapies



Researchers analyzing N439K Neutralization



Scientists testing COVID19 inhibitors



Diagnostic kits R&D



Government research organizations